(CercleFinance.com) – Merck today presents results from a phase III trial evaluating Keytruda as adjuvant treatment for patients with localized muscle invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma .
At the first interim analysis, after a median follow-up of 22.3 months, Keytruda demonstrated a ‘statistically and clinically significant’ improvement in disease-free survival (DFS), one of the two primary endpoints of the disease. ‘study.
In fact, the treatment reduced the risk of disease recurrence or death by 31% compared to observation of patients after surgery.
However, the other primary endpoint – overall survival (OS) – did not reach statistical significance at the time of this interim analysis.
Thus, after a median follow-up of 36.9 months, the median OS was 50.9 months for Keytruda compared to 55.8 months for observation after intervention.
Overall survival will therefore continue to be monitored as the data matures, reports the laboratory.
“The results of this pivotal study support Keytruda as a potential new adjuvant option for these patients and demonstrate its growing role in early stages of bladder cancer,” said Dr. Marjorie Green, senior vice president and head of oncology and global clinical development at Merck Research Laboratories.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
